Tags

Type your tag names separated by a space and hit enter

Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
JCI Insight 2020; 5(1)JI

Abstract

Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease progression. Although the mechanism(s) that mediate pathogenesis in the subpial compartment remain unclear, it has been speculated that inflammation in the overlying meninges may be associated with subpial injury. Here we show that adoptive transfer of proteolipid protein-primed Th17 cells into SJL/J recipient mice induces subpial demyelination associated with microglial/macrophage activation, disruption of the glial limitans, and evidence of an oxidative stress response. This pathology was topologically associated with foci of immune cells in the meninges and occurred in the absence of measurable anti-myelin oligodendrocyte glycoprotein IgM or IgG antibodies. To test the role of brain-infiltrating leukocytes on subpial injury, we modulated sphingosine 1-phosphate (S1P) receptor1,5 activity with BAF312 (siponimod) treatment. Administration of BAF312, even after adoptively transferred T cells had entered the brain, significantly ameliorated clinical experimental autoimmune encephalomyelitis and diminished subpial pathology, concomitant with a selective reduction in the capacity of transferred T cells to make Th17 cytokines. We conclude that sustained subpial cortical injury is associated with the capacity for brain-resident T cells to produce Th17 cytokines, and this pathological process occurs in an S1P receptor1,5-dependent manner.

Authors+Show Affiliations

Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Institute of Immunobiology, Kantonsspital St Gallen, St Gallen, Switzerland.Novartis Institutes for BioMedical Research, Basel, Switzerland.Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Department of Immunology, University of Toronto, Toronto, Ontario, Canada.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31821174

Citation

Ward, Lesley A., et al. "Siponimod Therapy Implicates Th17 Cells in a Preclinical Model of Subpial Cortical Injury." JCI Insight, vol. 5, no. 1, 2020.
Ward LA, Lee DS, Sharma A, et al. Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury. JCI Insight. 2020;5(1).
Ward, L. A., Lee, D. S., Sharma, A., Wang, A., Naouar, I., Ma, X. I., ... Gommerman, J. L. (2020). Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury. JCI Insight, 5(1), doi:10.1172/jci.insight.132522.
Ward LA, et al. Siponimod Therapy Implicates Th17 Cells in a Preclinical Model of Subpial Cortical Injury. JCI Insight. 2020 Jan 16;5(1) PubMed PMID: 31821174.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury. AU - Ward,Lesley A, AU - Lee,Dennis Sw, AU - Sharma,Anshu, AU - Wang,Angela, AU - Naouar,Ikbel, AU - Ma,Xianjie I, AU - Pikor,Natalia, AU - Nuesslein-Hildesheim,Barbara, AU - Ramaglia,Valeria, AU - Gommerman,Jennifer L, Y1 - 2020/01/16/ PY - 2019/08/09/received PY - 2019/11/25/accepted PY - 2019/12/11/pubmed PY - 2019/12/11/medline PY - 2019/12/11/entrez KW - Immunology KW - Mouse models KW - Multiple sclerosis KW - T cells JF - JCI insight JO - JCI Insight VL - 5 IS - 1 N2 - Subpial demyelination is a specific hallmark of multiple sclerosis and a correlate of disease progression. Although the mechanism(s) that mediate pathogenesis in the subpial compartment remain unclear, it has been speculated that inflammation in the overlying meninges may be associated with subpial injury. Here we show that adoptive transfer of proteolipid protein-primed Th17 cells into SJL/J recipient mice induces subpial demyelination associated with microglial/macrophage activation, disruption of the glial limitans, and evidence of an oxidative stress response. This pathology was topologically associated with foci of immune cells in the meninges and occurred in the absence of measurable anti-myelin oligodendrocyte glycoprotein IgM or IgG antibodies. To test the role of brain-infiltrating leukocytes on subpial injury, we modulated sphingosine 1-phosphate (S1P) receptor1,5 activity with BAF312 (siponimod) treatment. Administration of BAF312, even after adoptively transferred T cells had entered the brain, significantly ameliorated clinical experimental autoimmune encephalomyelitis and diminished subpial pathology, concomitant with a selective reduction in the capacity of transferred T cells to make Th17 cytokines. We conclude that sustained subpial cortical injury is associated with the capacity for brain-resident T cells to produce Th17 cytokines, and this pathological process occurs in an S1P receptor1,5-dependent manner. SN - 2379-3708 UR - https://www.unboundmedicine.com/medline/citation/31821174/Siponimod_therapy_implicates_Th17_cells_in_a_preclinical_model_of_subpial_cortical_injury L2 - https://doi.org/10.1172/jci.insight.132522 DB - PRIME DP - Unbound Medicine ER -